Are Options Traders Bullish on ADAP?
Let daily Option Order Flow show you where stock investors are Bullish and Bearish!!! Receive a FREE daily email of the Market Chameleon Order Flow Sentiment Newsletter.
Market Chameleon

About ADAP

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the Company aims to utilize the bodys own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity T-cell receptors (TCRs) as a means of strengthening natural patient T-cell responses. Adaptimmunes lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. As of June 30, 2015, 85 patients had been treated with Adaptimmunes NY-ESO TCR therapeutic: 47 under Adaptimmunes IND, and 38 under a National Cancer Institute IND. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. The Company currently has over 150 employees.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ADAP is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ADRD Invesco BLDRS Developed Markets 100 ADR Index Fund 42.4 M 4.24E+07 83 83 0.01% 0.0001 4 K 4175
ADRU Invesco BLDRS Europe Select ADR Index Fund 13.0 M 1.3E+07 69 69 0.01% 0.00012 2 K 1560
BIB ProShares Ultra Nasdaq Biotechnology 277.5 M 2.77548E+08 235 235 0.02% 0.000180169 110 K 109768
IBB iShares Nasdaq Biotechnology Index Fund 8.3 B 8.27384E+09 224 224 0.05% 0.0005 4.0 M 4048120
UBIO Proshares UltraPro Nasdaq Biotechnology 35.2 M 3.52295E+07 229 229 0.01% 0.000108008 12 K 12495

Wait, Before You Leave...